Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study.
Bridgewater J, Fletcher P, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M, Wasan H, Ross P, Wall L, Wadsley J, Evans TR, Stocken D, Stubbs C, Praseedom R, Ma YT, Davidson B, Neoptolemos J, Iveson T, Cunningham D, Garden OJ, Valle JW, Primrose J; BILCAP study group.
Bridgewater J, et al. Among authors: palmer dh.
J Clin Oncol. 2022 Jun 20;40(18):2048-2057. doi: 10.1200/JCO.21.02568. Epub 2022 Mar 22.
J Clin Oncol. 2022.
PMID: 35316080
Clinical Trial.
PURPOSE: The BILCAP study described a modest benefit for capecitabine as adjuvant therapy for curatively resected biliary tract cancer (BTC), and capecitabine has become the standard of care. We present the long-term data and novel exploratory subgroup analyses. METHODS: T …
PURPOSE: The BILCAP study described a modest benefit for capecitabine as adjuvant therapy for curatively resected biliary tract cancer (BTC) …